Halozyme Therapeutics, Inc. (HALO)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
HALO Insider Trading Activity
HALO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $19,934,663 | 39 | 100 |
Related Transactions
| Henderson Jeffrey William | director | 0 | $0 | 3 | $1.08M | $-1.08M |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | 0 | $0 | 4 | $1.83M | $-1.83M |
| Posard Matthew L. | director | 0 | $0 | 5 | $2.7M | $-2.7M |
| Torley Helen | PRESIDENT AND CEO | 0 | $0 | 11 | $6.26M | $-6.26M |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 0 | $0 | 16 | $8.08M | $-8.08M |
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Insider Activity of Halozyme Therapeutics, Inc.
Over the last 12 months, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $19.93M worth of Halozyme Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $16.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 52,629 shares for transaction amount of $748,697 was made by Kelley Kenneth J (director) on 2020‑03‑19.
List of Insider Buy and Sell Transactions, Halozyme Therapeutics, Inc.
| 2025-03-03 | Sale | Henderson Jeffrey William | director | 5,000 0.0041% | $58.69 | $293,458 | +6.01% | |
| 2025-02-27 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 1,697 0.0014% | $58.28 | $98,902 | +6.14% | |
| 2025-02-26 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0082% | $58.12 | $581,244 | +5.17% | |
| 2025-02-25 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0082% | $58.05 | $580,534 | +5.22% | |
| 2025-02-03 | Sale | Henderson Jeffrey William | director | 5,000 0.0039% | $56.30 | $281,517 | +3.94% | |
| 2025-01-06 | Sale | Henderson Jeffrey William | director | 10,000 0.0078% | $50.01 | $500,060 | +14.71% | |
| 2024-10-16 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0074% | $53.26 | $532,590 | +2.96% | |
| 2024-10-15 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0075% | $53.75 | $537,469 | +1.82% | |
| 2024-10-09 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0073% | $52.58 | $525,783 | +6.87% | |
| 2024-10-08 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0075% | $54.00 | $539,961 | -0.15% | |
| 2024-09-26 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0076% | $56.10 | $560,970 | -4.03% | |
| 2024-09-25 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0076% | $56.34 | $563,370 | -1.92% | |
| 2024-09-24 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0079% | $58.21 | $582,100 | -2.06% | |
| 2024-09-18 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0079% | $62.03 | $620,316 | -10.93% | |
| 2024-09-17 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.008% | $62.88 | $628,780 | -10.17% | |
| 2024-09-12 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0077% | $59.20 | $592,030 | -7.83% | |
| 2024-09-11 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0079% | $59.09 | $590,870 | -5.99% | |
| 2024-09-10 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0079% | $59.09 | $590,890 | -5.76% | |
| 2024-08-21 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0078% | $61.75 | $617,470 | -9.25% | |
| 2024-08-20 | Sale | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0079% | $61.05 | $610,550 | -7.22% |
Insider Historical Profitability
| Torley Helen | PRESIDENT AND CEO | 676744 0.5495% | $44.1M | 1 | 44 | +68.25% |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 173756 0.1411% | $11.32M | 0 | 48 | |
| Posard Matthew L. | director | 69874 0.0567% | $4.55M | 0 | 8 | |
| Henderson Jeffrey William | director | 33611 0.0273% | $2.19M | 0 | 6 | |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | 15480 0.0126% | $1.01M | 0 | 6 | |
| Frost Gregory Ian | CEO, President | 3555331 2.8869% | $231.67M | 4 | 16 | +20.07% |
| KIRK RANDAL J | 10 percent owner | 1897610 1.5409% | $123.65M | 56 | 18 | +103.3% |
| Lim Jonathan E | President, CEO | 680000 0.5522% | $44.31M | 1 | 8 | +18.01% |
| RAMSAY DAVID A | VP and Chief Financial Officer | 323492 0.2627% | $21.08M | 7 | 3 | +24.44% |
| FALBERG KATHRYN E | director | 280000 0.2274% | $18.24M | 3 | 0 | +46.53% |
| Engler Robert | director | 273176 0.2218% | $17.8M | 5 | 3 | +18.07% |
| MATSUI CONNIE | director | 181983 0.1478% | $11.86M | 0 | 2 | |
| PATTON JOHN STUART | director | 179876 0.1461% | $11.72M | 0 | 22 | |
| Kelley Kenneth J | director | 179833 0.146% | $11.72M | 3 | 22 | +50.56% |
| Yocum Richard C | VP Clinical Development | 65975 0.0536% | $4.3M | 0 | 1 | |
| BIZZARI JEAN-PIERRE | director | 52544 0.0427% | $3.42M | 0 | 1 | |
| Chondros Dimitrios | SVP, Chief Medical Officer | 38584 0.0313% | $2.51M | 0 | 2 | |
| Shaffer James P | VP & Chief Commercial Officer | 26300 0.0214% | $1.71M | 1 | 0 | +34.45% |
| Daly James M | director | 20503 0.0166% | $1.34M | 0 | 4 | |
| Thornton Steven T | director | 15000 0.0122% | $977,400.00 | 0 | 3 | |
| Shepard H. Michael | VP, Chief Scientific Officer | 13198 0.0107% | $859,981.68 | 0 | 1 | |
| LITTLE ROBERT J | VP, Chief Commercial Officer | 13000 0.0106% | $847,080.00 | 2 | 0 | <0.0001% |
| Stelzer Laurie | Chief Financial Officer | 10000 0.0081% | $651,600.00 | 1 | 0 | <0.0001% |
| GUSTAFSON KURT A | Vice President and CFO | 8000 0.0065% | $521,280.00 | 1 | 0 | |
| Kennard Don A | Vice President, Regulatory Aff | 3000 0.0024% | $195,480.00 | 1 | 0 | +31.79% |
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $11.98B | |
$159,914,414 | 243 | 18.52% | $6.19B | |
$211,610,344 | 91 | 38.45% | $7.54B | |
$2,765,836 | 72 | 20.00% | $13.59B | |
Halozyme Therapeutics, Inc. (HALO) | $108,876,545 | 67 | 72.81% | $8.02B |
$42,463,802 | 57 | 17.85% | $7.19B | |
$11,789,714 | 49 | 14.35% | $14.47B | |
$88,307,390 | 38 | -1.70% | $8.43B | |
$13,655,378 | 35 | 17.13% | $14.06B | |
$10,499,766 | 34 | 70.55% | $10.34B | |
$415,105,240 | 19 | -14.04% | $6.61B | |
$1,279,017 | 16 | 51.12% | $6.18B | |
$83,065,496 | 16 | 9.40% | $7.09B | |
$948,235 | 8 | 15.56% | $9.58B | |
$2,246,813 | 6 | 70.15% | $6.75B | |
$4,849,105 | 4 | 2.71% | $5.67B | |
$41,376,000 | 4 | -12.07% | $9.61B | |
$40,276,273 | 4 | 34.57% | $7.7B | |
$999,989 | 1 | 262.16% | $12.6B |
HALO Institutional Investors: Active Positions
| Increased Positions | 263 | +43.98% | 13M | +10.45% |
| Decreased Positions | 265 | -44.31% | 16M | -12.38% |
| New Positions | 92 | New | 4M | New |
| Sold Out Positions | 83 | Sold Out | 4M | Sold Out |
| Total Postitions | 596 | -0.33% | 123M | -1.93% |
HALO Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $1.09M | 14.28% | 17.57M | +136,136 | +0.78% | 2024-12-31 |
| Vanguard Group Inc | $827,052.00 | 10.8% | 13.28M | +386,618 | +3% | 2024-12-31 |
| State Street Corp | $447,387.00 | 5.84% | 7.18M | +550,948 | +8.3% | 2024-12-31 |
| Snyder Capital Management L P | $259,570.00 | 3.39% | 4.17M | +105,086 | +2.59% | 2024-12-31 |
| Bank Of America Corp /De/ | $214,731.00 | 2.8% | 3.45M | +1M | +66.63% | 2024-12-31 |
| Alliancebernstein L.P. | $191,071.00 | 2.5% | 3.07M | -339,909 | -9.97% | 2024-12-31 |
| Geode Capital Management, Llc | $190,800.00 | 2.49% | 3.06M | +3,941 | +0.13% | 2024-12-31 |
| Macquarie Group Ltd | $180,925.00 | 2.36% | 2.91M | -105,340 | -3.5% | 2024-12-31 |
| Jpmorgan Chase & Co | $148,669.00 | 1.94% | 2.39M | -477,368 | -16.66% | 2024-12-31 |
| Invesco Ltd. | $147,855.00 | 1.93% | 2.37M | +462,762 | +24.21% | 2024-12-31 |